Renal cell CA, recurrent renal cancer, kidney mass, SBRT, small bowel dose constraints, bladder management during treatment, boost dose,

Stage II seminoma, testicular tumor, second malignancies, BEP chemotherapy, PSA, hypofractionation,

Stage IV prostate, tissue sparing, discordant PSA and biopsy, Gleason score, treatment, margins for SBRT, patient selection,

Prostate cancer, mesenteric disease, palliative care, muscle invasive bladder carcinoma, bladder mass, bladder preservation, Gleason 3 + 3

Pro PSMA trial looking at utility of PSMA scan for initial staging for high risk prostate cancer, metastatic disease, PSMA, pelvic nodal fields, long term outcomes

ADT timing, duration of ADT in high risk patients, dementia and alzheimer's risk, ADT outcome, toxicity, atlas study, biochemical relapse

Gleason 9 and Gleason 10 adenocarcinoma, rectal wall invasion, prostate active surveillance guidelines, Polaris test, PSA frequency, core volumes

IB seminoma, recurrent seminoma, salvage therapy, prostate, external beam and brachytherapy, spaceoar, bladder preservation, Ca of bladder

Nodes, radiotherapy, and prostate cancer, elective nodal radiation, short term ADT, imaging with PET, pelvic nodal radiation, prostate adenocarcinoma,

prostate adenocarcinoma, Gleason 4+4, dose, long term outcomes, ADT, GETUG-01, pelvic lymph node treatment fields, adenocarcinoma of the prostate, prostate radiation

High risk prostate cancer, prostate acing adenocarcinoma, bladder invasion, systemic therapy, ADT, rectal invasion, germline testing, BPH

Prostate cancer, Gleason 9, stage IV, treatment volume, femoral lesion, muscle invasive carcinoma, metastatic bladder cancer, oligometastatic disease,

Adenocarcinoma, RT fields, watchful waiting, axumin PET timing, patient management, local salvage therapy

GU ASTRO trials, prostate salvage treatment, treatment duration, ADT, adrenal carcinoma, treatment near the bowel

Prostate ca, DVH, treatment near bowel, DVH, post-prostectomy radiation, urinary incontinence, ADT in salvage therapy, PSA, salvage radiation

NRG Oncology, genomic classification, managing high risk patients, long term ADT, pelvic nodal radiation, treatment intensification, adjuvant vs. early salvage,

advanced prostate cancer, perirectal lymph nodes, seminal vesicle and prostate dose, bone mets, immune response, toxicity, metastatic sites

High risk prostate with castration, castration resistant, axumin pet scan, imaging trials, PSMA for initial staging, axumin vs PSMA, intraductal prostate carcinomas, prostate screening

Unfavorable intermediate risk prostate cancer, doubling time of 10.4 months, RT proctitis, SBRT, treatment,

Revolutionary vs. Evolutionary: adjuvant vs neoadjuvant ADT, research in PSMA technology, radiation for oligometastatic prostate cancer

oral agent vs. injection HERO trial, timing of RT, IMRT radiotherapy, salvage radiation, dose, ADT tradeoffs, prostate ca

Postprostatectomy salvage radiotherapy, ADT and SBRT, seminal vesicle invasion, seminal vesicle MRI readings, nodal radiation